Dr. Rosenbluth is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3800
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2013 - 2017
- Massachusetts General HospitalResidency, Internal Medicine, 2011 - 2013
- Vanderbilt University School of MedicineClass of 2011
Certifications & Licensure
- CA State Medical License 2021 - 2025
- MA State Medical License 2014 - 2023
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Implantation of engineered adipocytes suppresses tumor progression in cancer models.Hai P Nguyen, Kelly An, Yusuke Ito, Bhushan N Kharbikar, Rory Sheng
Nature Biotechnology. 2025-02-04 - T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation.Nam Woo Cho, Sophia M Guldberg, Barzin Y Nabet, Jie Zeng Yu, Eun Ji Kim
Cancer Immunology Research. 2025-02-03 - Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.Kirithiga Ramalingam, Rachel Woody, Alexa Glencer, Christopher J Schwartz, Hidetoshi Mori
JAMA Oncology. 2025-01-16
Press Mentions
- CRISPR Transforms Ordinary Fat Cells into Cancer Killing MachinesFebruary 25th, 2025
- Engineered Adipocytes Target Tumor Growth in Cancer ModelsFebruary 6th, 2025
- CRISPR-Engineered Fat Cells Show Promise in Preclinical Cancer ModelsFebruary 5th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: